Evidence map›Paper›PMID 34076828›Full record

ArticleJournal of cell communication and signaling2022

Is the mechanism of COVID-19 coagulopathy still a rabbit's hole?

Ashna Rajan, Ganesh Keshav Thirunavukkarasu, Richard F Lockey, Narasaiah Kolliputi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cell communication and signaling, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ashna RajanDivision of Geriatrics Medicine, Brown University Alpert School of Medicine, Providence, RI, 02903, USA.
Ganesh Keshav ThirunavukkarasuDivision of Cardiovascular Medicine, Department of Internal Medicine, State University of New York-Downstate Medical Center, Brooklyn, NY, 11203, USA.
Richard F LockeyDivision of Allergy and Immunology, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, 2901 Bruce B. Downs Blvd, Tampa, FL, 33612, USA.
Narasaiah KolliputiDivision of Allergy and Immunology, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, 2901 Bruce B. Downs Blvd, Tampa, FL, 33612, USA. nkollipu@usf.edu.ORCID http://orcid.org/0000-0002-2654-1900

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The pathophysiology of COVID-19 is an enigma with its severity often determined by the extent of coagulopathy. Several regulatory pathways targeted by the SARS-CoV-2 include the renin-angiotensin system, von Willebrand Factor, and most importantly, the complement pathway. This article discusses these pathways to help design potential future therapies.

Indexed as

ACE2CoagulopathyComplementCOVID-19SARS-CoV2Thromboinflammation

Identifiers

PMID34076828
PMCPMC8170857

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.